Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
Collectively, the results of this study demonstrate the precise incidence and risk factors of ICI-T1DM. The development of ICI-T1DM, like other irAEs, is associated with higher survival rates.
Authors
- Tomoya Myojin (ORCID: https://orcid.org/0000-0002-3820-6157)
- Tatsuya Noda (ORCID: https://orcid.org/0000-0002-3652-7547)
- Yutaka Takahashi (ORCID: https://orcid.org/0000-0002-1337-9246)
- Tomoaki Imamura (ORCID: https://orcid.org/0000-0003-1981-9959)
- Hiroki Nakajima (ORCID: https://orcid.org/0000-0003-0518-8156)
- Fumika Kamitani (ORCID: https://orcid.org/0000-0002-2838-7986)
- Yuichi Nishioka (ORCID: https://orcid.org/0000-0002-1956-3925)
- Sadanori Okada (ORCID: https://orcid.org/0000-0002-3097-8152)
- Shinichiro Kubo (ORCID: https://orcid.org/0000-0002-9090-7399)
- Yukako Kurematsu
- Miyuki Koizumi (ORCID: https://orcid.org/0009-0004-0837-5365)
Institutions
- Nara Medical University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1111/jdi.14362
- Citations
- 10
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.50
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Boehringer Ingelheim Japan
- Novo Nordisk
- Nara Medical University
- Japan Society for the Promotion of Science